It was reported that disease progression after EGFR TKI treatment leads to suppression of tumor-infiltrating CD8+ T cells and induction of regulatory T cells, resulting in a noninflamed TME and insensitivity to ICI monotherapy.18 Here, CD8A is linked to neoplasm.